The current results demonstrated that after 8 weeks of FRB treatment, rats in the HF + 5% FRB group had a significantly lower NAFLD score and hepatic IL-1β level, a decreasing trend of final BW and plasma leptin level, as well as an increase in beneficial bacteria in the gut microbiota. This evidence concerns the gene IL1B and metabolic dysfunction-associated steatotic liver disease.